Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Change in study parameters during the follow-up period

From: Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study

Cohort

Dulaglutide, n = 30

Liraglutide, n = 30

Parameter

Baseline Mean ± SEM

Follow-up Mean ± SEM

Change Mean ± SEM

P

Baseline Mean ± SEM

Follow-up Mean ± SEM

Change Mean ± SEM

P

Body weight (kg)

87.17 ± 2.16

82.97 ± 2.05

−4.20 ± 0.47

< 0.001

89.43 ± 2.60

83.60 ± 2.35

−5.83 ± 0.87

< 0.001

BMI (kg/m2)

32.84 ± 0.77

31.312 ± 0 .68

−1.53 ± 0.21

< 0.001

34.92 ± 0.868

32.650 ± 0.77

−2.27 ± 0.33

< 0.001

SBP (mmHg)

134.30 ± 2.71

130.87 ± 2.49

−3.43 ± 2.97

0.258

137.83 ± 2.503

127.60 ± 2.07

−10.23 ± 2.36

< 0.001

DBP (mmHg)

80.73 ± 1.64

78.43 ± 0.914

− 2.30 ± 1.79

0.208

83.47 ± 1.587

80.67 ± 1.51

− 2.80 ± 1.85

0.141

FPG(mg/dl)

175.53 ± 11.45

133.67 ± 6.90

− 41.87 ± 12.72

0.003

160.13 ± 8.17

115.93 ± 5.69

− 44.20 ± 8.05

< 0.001

HbA1c (%)

8.43 ± 0.21

7.411 ± 0.15

−1.017 ± 0.22

< 0.001

8.49 ± 0.26

6.95 ± 0.21

− 1.547 ± 0.22

< 0.001

Back to article page

Cardiovascular Diabetology – Endocrinology Reports

ISSN: 3059-4057

Contact us